

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,755	05/14/2001	David Elliott Spaner	033136-176	8477
7590 02/17/2004			EXAMINER	
Gerald F. Swiss, Esq.			EWOLDT, GERALD R	
BURNS, DOANE, SWECKER & MATHIS, L.L.P.				
P.O. Box 1404			ART UNIT	PAPER NUMBER
Alexandria, VA 22313-1404		1644		

DATE MAILED: 02/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/853,755	SPANER, DAVID ELLIOTT			
		Examiner	Art Unit			
		G. R. Ewoldt, Ph.D.	1644			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status -						
1)⊠	1)⊠ Responsive to communication(s) filed on <u>11/17/03</u> .					
2a)⊠	This action is FINAL . 2b) This	s action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims					
4) ⊠ Claim(s) 21 and 22 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 21, 22 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or election requirement.						
Applicat	ion Papers					
9)[The specification is objected to by the Examine	er.				
10)	The drawing(s) filed on is/are: a) acc					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No						
2) Notion Notion Notion Notion	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449 or PTO/SB/08 er No(s)/Mail Date	4) Interview Summan Paper No(s)/Mail D 5) Notice of Informal 6) Other:				

DETAILED ACTION

- 1. Applicant's remarks, filed 11/17/03, are acknowledged.
- 2. Claims 21 and 22 are pending and being acted upon.
- 3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in-
- (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effect under this subsection of a national application published under section 122(b) only if the international application designating the United States was published under Article 21(2)(a) of such treaty in the English language; or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).
- 4. Claims 21 and 22 stand rejected under 35 U.S.C. 102(e) as being clearly anticipated by U.S. Patent No. 5,980,954, for the reasons of record as set forth in the action mailed 8/19/03.
- 5. Claims 21 and 22 stand rejected under 35 U.S.C. 102(b) as being clearly anticipated by W0 98/07436 (IDS), for the reasons of record as set forth in the action mailed 8/19/03.

Note: Applicant has argued the rejections together, accordingly the Examiner's response relates to both rejections.

Applicant's arguments, filed 11/18/03, have been fully considered but they are not persuasive. Applicant argues, "Applicant submits that the cited prior art does not disclose the use of either PBMC or mammalian T-cells, much less such cell populations that are essentially free of stem cells". Applicant further argues, "The apparent failure of the Office Action to recognize the distinction between these claim terms is troubling since the rejections under 35 U.S.C. 102 appear to be based on the particular constituent cells present in the cell populations described in the cited prior art and in the instant application."

Applicant's "troubles" aside, Applicant is advised that the references teach blood that been subjected in vitro to oxidative stress. Blood comprises PBMC, but more importantly, blood comprises "a population of mammalian T cells". Because stem cells comprise such a rare cell type (well under 1%), blood can be considered to be "essentially free of stem cells". Accordingly, the references teach the claimed invention.

Applicant argues "Additionally, there is abundant evidence in the Specifications of the cited references to convince one skilled in the art that the cell populations described for use in preferred embodiments of the respective inventions are not PBMC or mammalian T-cells (the presence or absence of stem cells aside)."

Applicant is advised that the "preferred embodiments" of the prior art are unrelated to the patentability of the invention of the instant claims. The invention of the instant claims is just that - the invention defined by the instant claims. The prior art need only teach the invention defined by the instant claims to comprise prior art. Accordingly, the rejections are proper and have been maintained.

6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805 The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973.

Serial No. 09/853,755 Art Unit 1644

8. Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

G.R. Ewoldt, Ph.D. Primary Examiner Technology Center 1600

G.R. EWOUDT, FH.D. BRIMARY EXAMINER